Data | Hora | Fonte | Título | Código | Companhia |
20/07/2009 | 09:04 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (S-8) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
20/07/2009 | 09:00 | Edgar (US Regulatory) | Securities Registration Statement (simplified form) (S-3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
20/07/2009 | 08:55 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/07/2009 | 09:07 | Marketwired | BridgewaterEquity.com Free Fundamental Sector & Market Research on OCR, GGC, NWD, MPW, ALTH and NEXM | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/07/2009 | 09:00 | Business Wire | Allos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
29/06/2009 | 09:40 | PR Newswire (US) | InvestorSoup.com Researches Market Movers: Applied Materials, Allscripts-Misys, Allos, ValueVision, BGC Partners and Warren Reso | NASDAQ:ALTH | |
23/06/2009 | 19:46 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
02/06/2009 | 07:05 | Edgar (US Regulatory) | Proxy Statement (definitive) (DEF 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
30/05/2009 | 09:00 | Business Wire | Allos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/05/2009 | 09:00 | Business Wire | Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
14/05/2009 | 19:15 | Business Wire | Allos Therapeutics Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
12/05/2009 | 09:00 | Business Wire | Allos Therapeutics to Present at the Eighth Annual JMP Securities Research Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/05/2009 | 18:01 | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/05/2009 | 17:00 | Business Wire | Allos Therapeutics Reports First Quarter 2009 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
30/04/2009 | 09:31 | Edgar (US Regulatory) | Amended Annual Report (10-K/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/04/2009 | 17:00 | Business Wire | Allos Therapeutics to Report First Quarter 2009 Results on May 5, 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
19/04/2009 | 16:00 | Business Wire | Allos Therapeutics’ Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
15/04/2009 | 09:00 | Business Wire | Allos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
03/04/2009 | 17:00 | Business Wire | Allos Therapeutics Announces Closing of Common Stock Offering | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
02/04/2009 | 17:10 | Edgar (US Regulatory) | Prospectus filed pursuant to Rule 424(b)(5) (424B5) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
31/03/2009 | 10:00 | Business Wire | Allos Therapeutics Announces Pricing of Common Stock Offering | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/03/2009 | 09:00 | Business Wire | Allos Therapeutics to Present at the 4th Annual Citi Biotech Day | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
25/03/2009 | 09:00 | Business Wire | Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell L... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/03/2009 | 18:30 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/03/2009 | 09:00 | Business Wire | Allos Therapeutics Appoints David M. Stout to Its Board of Directors | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
17/03/2009 | 09:00 | Business Wire | Allos Therapeutics’ Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the Eu... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
03/03/2009 | 18:00 | Business Wire | Allos Therapeutics Reports 2008 Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/02/2009 | 18:00 | Business Wire | Allos Therapeutics to Report 2008 Results on March 3, 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
17/02/2009 | 18:24 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
13/02/2009 | 19:49 | Edgar (US Regulatory) | Annual Statement of Changes in Beneficial Ownership (5) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |